IDEXX Laboratories, Inc. (NASDAQ:IDXX) Holdings Lifted by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,748 shares of the company’s stock after purchasing an additional 1,286 shares during the quarter. Daiwa Securities Group Inc.’s holdings in IDEXX Laboratories were worth $7,338,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in IDEXX Laboratories by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company’s stock worth $1,138,732,000 after buying an additional 40,349 shares in the last quarter. Franklin Resources Inc. grew its holdings in IDEXX Laboratories by 2.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock worth $675,259,000 after buying an additional 34,305 shares in the last quarter. Amundi grew its holdings in IDEXX Laboratories by 8.1% in the 4th quarter. Amundi now owns 758,669 shares of the company’s stock worth $328,018,000 after buying an additional 56,837 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in IDEXX Laboratories by 0.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 751,900 shares of the company’s stock worth $379,875,000 after buying an additional 2,463 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in IDEXX Laboratories by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 531,692 shares of the company’s stock worth $219,823,000 after buying an additional 16,213 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling

In other news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.18% of the stock is currently owned by insiders.

IDEXX Laboratories Trading Down 2.2 %

Shares of NASDAQ:IDXX opened at $426.69 on Wednesday. The stock has a market capitalization of $34.70 billion, a price-to-earnings ratio of 39.99, a PEG ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $552.20. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a 50 day moving average price of $438.11 and a 200 day moving average price of $448.27.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of recent analyst reports. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday, March 7th. Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. Finally, Bank of America boosted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.